Abstract
Invasive meningococcal disease occurs worldwide causing an estimated 50,000–135,000 deaths each year in addition to significant sequelae. In developed countries the disease is usually sporadic but outbreaks and epidemics, usually due to serogroups B and C, have occurred. In the US, an increasing number of cases are due to serogroup Y. In developing nations, epidemics due to serogroups A and more recently W-135, are common. The tetravalent meningococcal conjugate vaccine to serogroups A, C, Y, and W-135 (MCV4) has been demonstrated to be highly immunogenic and promote immune memory. This article will describe the rationale for the vaccine and its potential role to significantly decrease mortality and morbidity of meningococcal disease in those areas and populations at greatest risk from these serogroups.
Disclosures
Dr. Kimmel owns shares in GSK, and is a member of GSK Family/General Practitioner Advisory Board for Cervical Cancer effective February 2008. He is a consultant for Merck, Inc., and on the speaker’s bureau, and a consultant for SanofiPasteur, and on the speaker’s bureau. He is also a consultant, CDC grant to Society of Teachers of Family Medicine Foundation for project “Increasing Immunizations by Family Physicians”. Richard Zimmerman, MD, MPH, University of Pittsburgh, is the primary investigator. Grant is now expired.